Abstract
MicroRNAs (miRNAs) are small, non-coding RNAs that have an important role in the regulation of carcinogenic pathways. The observations that miRNAs are differentially expressed in tumor versus corresponding normal tissue, and that they regulate important breakpoints during carcinogenesis, are of interest for urologic oncologists. As biomarkers, they might be helpful tools for diagnostic, prognostic and monitoring purposes. Furthermore, miRNAs might be potential targets for novel therapeutic strategies, especially in patients with tumor subtypes that do not respond to currently available therapies. In this Review, we will focus on the current proceedings of miRNA research in urologic tumors. In the past decade, the number of published articles related to miRNAs in urologic oncology has increased, highlighting the ongoing importance of miRNAs in this field. Current studies support the hypothesis that miRNA will gain influence in clinical practice. Here, therefore, we illustrate the current knowledge of miRNA function in urologic tumors and draw the attention of urologists to the future opportunities and challenges of this research field.
Key Points
-
MicroRNAs (miRNAs) have oncogenic and tumor-suppressive activities, and influence the proliferation, migration, and invasion of cells
-
miRNAs are deregulated in urologic tumors, and can be detected in fresh or archived tissue as well as in blood or urine
-
miRNAs are promising diagnostic and prognostic tumor markers and potential therapeutic tools
-
Identification of miRNA-regulated pathways may lead to a better understanding of the development and progression of urologic tumors
-
Manipulation of oncogenic or tumor-suppressive miRNAs might present novel therapeutic strategies for urologic tumors
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Kutter, C. & Svoboda, P. miRNA, siRNA, piRNA: knowns of the unknown. RNA Biol. 5, 181–188 (2008).
Pezer, Z. & Ugarkovic, D. Role of non-coding RNA and heterochromatin in aneuploidy and cancer. Semin. Cancer Biol. 18, 123–130 (2008).
Costa, F. F. Non-coding RNAs: lost in translation? Gene 386, 1–10 (2007).
Perez, D. S. et al. Long, abundantly expressed non-coding transcripts are altered in cancer. Hum. Mol. Genet. 17, 642–655 (2008).
Coppola, V., De Maria, R. & Bonci, D. MicroRNAs and prostate cancer. Endocr. Relat. Cancer 17, F1–F17 (2010).
DeVere White, R. W., Vinall, R. L., Tepper, C. G. & Shi, X. B. MicroRNAs and their potential for translation in prostate cancer. Urol. Oncol. 27, 307–311 (2009).
Gandellini, P., Folini, M. & Zaffaroni, N. Towards the definition of prostate cancer-related microRNAs: where are we now? Trends Mol. Med. 15, 381–390 (2009).
Shi, X. B., Tepper, C. G. & DeVere White, R. W. MicroRNAs and prostate cancer. J. Cell. Mol. Med. 12, 1456–1465 (2008).
Schaefer, A. et al. MicroRNAs and cancer: current state and future perspectives in urologic oncology. Urol. Oncol. 28, 4–13 (2010).
Metias, S. M., Lianidou, E. & Yousef, G. M. MicroRNAs in clinical oncology: at the crossroads between promises and problems. J. Clin. Pathol. 62, 771–776 (2009).
van den Berg, A., Mols, J. & Han, J. RISC-target interaction: cleavage and translational suppression. Biochim. Biophys. Acta 1779, 668–677 (2008).
Winter, J., Jung, S., Keller, S., Gregory, R. I. & Diederichs, S. Many roads to maturity: microRNA biogenesis pathways and their regulation. Nat. Cell Biol. 11, 228–234 (2009).
Pillai, R. S. et al. Inhibition of translational initiation by let-7 microRNA in human cells. Science 309, 1573–1576 (2005).
Lewis, B. P., Burge, C. B. & Bartel, D. P. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120, 15–20 (2005).
Pillai, R. S., Bhattacharyya, S. N. & Filipowicz, W. Repression of protein synthesis by miRNAs: how many mechanisms? Trends Cell Biol. 17, 118–126 (2007).
Berezikov, E. et al. Phylogenetic shadowing and computational identification of human microRNA genes. Cell 120, 21–24 (2005).
Schmittgen, T. D. et al. Real-time PCR quantification of precursor and mature microRNA. Methods 44, 31–38 (2008).
Leite, K. R. et al. miRNA analysis of prostate cancer by quantitative real time PCR: comparison between formalin-fixed paraffin embedded and fresh-frozen tissue. Urol. Oncol. doi: 10.1016/j.urolonc.2009.05.008.
Calin, G. A. et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc. Natl Acad. Sci. USA 101, 2999–3004 (2004).
Lu, J. et al. MicroRNA expression profiles classify human cancers. Nature 435, 834–838 (2005).
Volinia, S. et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc. Natl Acad. Sci. USA 103, 2257–2261 (2006).
Calin, G. A. & Croce, C. M. MicroRNA-cancer connection: the beginning of a new tale. Cancer Res. 66, 7390–7394 (2006).
Fabbri, M., Ivan, M., Cimmino, A., Negrini, M. & Calin, G. A. Regulatory mechanisms of microRNAs involvement in cancer. Expert Opin. Biol. Ther. 7, 1009–1019 (2007).
Boyerinas, B. et al. Identification of let-7-regulated oncofetal genes. Cancer Res. 68, 2587–2591 (2008).
Brueckner, B. et al. The human let-7a-3 locus contains an epigenetically regulated microRNA gene with oncogenic function. Cancer Res. 67, 1419–1423 (2007).
Cowland, J. B., Hother, C. & Gronbaek, K. MicroRNAs and cancer. APMIS 115, 1090–1106 (2007).
Mitchell, P. S. et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl Acad. Sci. USA 105, 10513–10518 (2008).
Lodes, M. J. et al. Detection of cancer with serum miRNAs on an oligonucleotide microarray. PLoS ONE 4, e6229 (2009).
Keller, A. et al. miRNAs in lung cancer—studying complex fingerprints in patient's blood cells by microarray experiments. BMC Cancer 9, 353 (2009).
Hanke, M. et al. A robust methodology to study urine microRNA as tumor marker: microRNA-126 and microRNA-182 are related to urinary bladder cancer. Urol. Oncol. doi:10.1016/j.urolonc.2009.01.027.
Wang, V. & Wu, W. MicroRNA-based therapeutics for cancer. BioDrugs 23, 15–23 (2009).
Lu, Y. et al. A single anti-microRNA antisense oligodeoxyribonucleotide (AMO) targeting multiple microRNAs offers an improved approach for microRNA interference. Nucleic Acids Res. 37, e24 (2009).
Krutzfeldt, J. et al. Silencing of microRNAs in vivo with 'antagomirs'. Nature 438, 685–689 (2005).
Fontana, L. et al. Antagomir-17-5p abolishes the growth of therapy-resistant neuroblastoma through p21 and BIM. PLoS ONE 3, e2236 (2008).
Ebert, M. S., Neilson, J. R. & Sharp, P. A. MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells. Nat. Methods 4, 721–726 (2007).
Sayed, D. et al. MicroRNA-21 targets sprouty2 and promotes cellular outgrowths. Mol. Biol. Cell 19, 3272–3282 (2008).
Davalos, V. & Esteller, M. MicroRNAs and cancer epigenetics: a macrorevolution. Curr. Opin. Oncol. 22, 35–45 (2010).
Saito, Y. et al. Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell 9, 435–443 (2006).
Lee, C. Y., Rennie, P. S. & Jia, W. W. MicroRNA regulation of oncolytic herpes simplex virus-1 for selective killing of prostate cancer cells. Clin. Cancer Res. 15, 5126–5135 (2009).
Josson, S., Sung, S. Y., Lao, K., Chung, L. W. & Johnstone, P. A. Radiation modulation of microRNA in prostate cancer cell lines. Prostate 68, 1599–1606 (2008).
Porkka, K. P. et al. MicroRNA expression profiling in prostate cancer. Cancer Res. 67, 6130–6135 (2007).
Ozen, M., Creighton, C. J., Ozdemir, M. & Ittmann, M. Widespread deregulation of microRNA expression in human prostate cancer. Oncogene 27, 1788–1793 (2008).
Ambs, S. et al. Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. Cancer Res. 68, 6162–6170 (2008).
Schaefer, A. et al. Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int. J. Cancer 126, 1166–1176 (2010).
Tong, A. W. et al. MicroRNA profile analysis of human prostate cancers. Cancer Gene Ther. 16, 206–216 (2009).
Spahn, M. et al. Expression of microRNA-221 is progressively reduced in aggressive prostate cancer and metastasis and predicts clinical recurrence. Int. J. Cancer doi:10.1002/ijc.24715.
Lin, S. L., Chiang, A., Chang, D. & Ying, S. Y. Loss of mir-146a function in hormone-refractory prostate cancer. RNA 14, 417–424 (2008).
Prueitt, R. L. et al. Expression of microRNAs and protein-coding genes associated with perineural invasion in prostate cancer. Prostate 68, 1152–1164 (2008).
Leite, K. R. et al. Change in expression of miR-let7c, miR-100, and miR-218 from high grade localized prostate cancer to metastasis. Urol. Oncol. doi:10.1016/j.urolonc.2009.02.002.
Mattie, M. D. et al. Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies. Mol. Cancer 5, 24 (2006).
Shi, X. B. et al. An androgen-regulated miRNA suppresses Bak1 expression and induces androgen-independent growth of prostate cancer cells. Proc. Natl Acad. Sci. USA 104, 19983–19988 (2007).
DeVere White, R. W., Vinall, R. L., Tepper, C. G. & Shi, X. B. MicroRNAs and their potential for translation in prostate cancer. Urol. Oncol. 27, 307–311 (2009).
Lee, Y. S., Kim, H. K., Chung, S., Kim, K. S. & Dutta, A. Depletion of human micro-RNA miR-125b reveals that it is critical for the proliferation of differentiated cells but not for the down-regulation of putative targets during differentiation. J. Biol. Chem. 280, 16635–16641 (2005).
Sun, T. et al. The role of microRNA-221 and microRNA-222 in androgen-independent prostate cancer cell lines. Cancer Res. 69, 3356–3363 (2009).
Galardi, S. et al. miR-221 and miR-222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27Kip1. J. Biol. Chem. 282, 23716–23724 (2007).
Mercatelli, N. et al. The inhibition of the highly expressed miR-221 and miR-222 impairs the growth of prostate carcinoma xenografts in mice. PLoS ONE 3, e4029 (2008).
Ribas, J. et al. miR-21: an androgen receptor-regulated microRNA that promotes hormone-dependent and hormone-independent prostate cancer growth. Cancer Res. 69, 7165–7169 (2009).
Li, T., Li, D., Sha, J., Sun, P. & Huang, Y. MicroRNA-21 directly targets MARCKS and promotes apoptosis resistance and invasion in prostate cancer cells. Biochem. Biophys. Res. Commun. 383, 280–285 (2009).
Qin, W. et al. BMPRII is a direct target of miR-21. Acta Biochim. Biophys. Sin. (Shanghai) 41, 618–623 (2009).
Lu, Z. et al. MicroRNA-21 promotes cell transformation by targeting the programmed cell death 4 gene. Oncogene 27, 4373–4379 (2008).
Cimmino, A. et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc. Natl Acad. Sci. USA 102, 13944–13949 (2005).
Bonci, D. et al. The miR-15a–miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat. Med. 14, 1271–1277 (2008).
Takeshita, F. et al. Systemic delivery of synthetic microRNA-16 inhibits the growth of metastatic prostate tumors via downregulation of multiple cell-cycle genes. Mol. Ther. 18, 181–187 (2010).
Lee, K. H. et al. MicroRNA-330 acts as tumor suppressor and induces apoptosis of prostate cancer cells through E2F1-mediated suppression of Akt phosphorylation. Oncogene 28, 3360–3370 (2009).
Sylvestre, Y. et al. An E2F/miR-20a autoregulatory feedback loop. J. Biol. Chem. 282, 2135–2143 (2007).
Rokhlin, O. W. et al. MicroRNA-34 mediates AR-dependent p53-induced apoptosis in prostate cancer. Cancer Biol. Ther. 7, 1288–1296 (2008).
Fujita, Y. et al. Effects of miR-34a on cell growth and chemoresistance in prostate cancer PC3 cells. Biochem. Biophys. Res. Commun. 377, 114–119 (2008).
Lodygin, D. et al. Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer. Cell Cycle 7, 2591–2600 (2008).
Hugo, H. et al. Epithelial-mesenchymal and mesenchymal-epithelial transitions in carcinoma progression. J. Cell. Physiol. 213, 374–383 (2007).
Gandellini, P. et al. miR-205 exerts tumor-suppressive functions in human prostate through down-regulation of protein kinase Cε. Cancer Res. 69, 2287–2295 (2009).
Kong, D. et al. miR-200 regulates PDGF-D-mediated epithelial–mesenchymal transition, adhesion, and invasion of prostate cancer cells. Stem Cells 27, 1712–1721 (2009).
Yang, K., Handorean, A. M. & Iczkowski, K. A. MicroRNAs 373 and 520c are downregulated in prostate cancer, suppress CD44 translation and enhance invasion of prostate cancer cells in vitro. Int. J. Clin. Exp. Pathol. 2, 361–369 (2009).
Place, R. F., Li, L. C., Pookot, D., Noonan, E. J. & Dahiya, R. MicroRNA-373 induces expression of genes with complementary promoter sequences. Proc. Natl Acad. Sci. USA 105, 1608–1613 (2008).
Zhang, X. et al. MicroRNA-17-3p is a prostate tumor suppressor in vitro and in vivo, and is decreased in high grade prostate tumors analyzed by laser capture microdissection. Clin. Exp. Metastasis 26, 965–979 (2009).
Noonan, E. J. et al. miR-449a targets HDAC-1 and induces growth arrest in prostate cancer. Oncogene 28, 1714–1724 (2009).
Wedel, S. A. et al. New histone deacetylase inhibitors as potential therapeutic tools for advanced prostate carcinoma. J. Cell. Mol. Med. 12, 2457–2466 (2008).
Weichert, W. et al. Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. Br. J. Cancer 98, 604–610 (2008).
Saito, Y. et al. Epigenetic therapy upregulates the tumor suppressor microRNA-126 and its host gene EGFL7 in human cancer cells. Biochem. Biophys. Res. Commun. 379, 726–731 (2009).
Varambally, S. et al. Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science 322, 1695–1699 (2008).
Gottardo, F. et al. Micro-RNA profiling in kidney and bladder cancers. Urol. Oncol. 25, 387–392 (2007).
Ichimi, T. et al. Identification of novel microRNA targets based on microRNA signatures in bladder cancer. Int. J. Cancer 125, 345–352 (2009).
Wang, G. et al. Up-regulation of microRNA in bladder tumor tissue is not common. Int. Urol. Nephrol. doi:10.1007/s11255-009-9584-3.
Lin, T. et al. MicroRNA-143 as a tumor suppressor for bladder cancer. J. Urol. 181, 1372–1380 (2009).
Dyrskjot, L. et al. Genomic profiling of microRNAs in bladder cancer: miR-129 is associated with poor outcome and promotes cell death in vitro. Cancer Res. 69, 4851–4860 (2009).
Friedman, J. M. et al. The putative tumor suppressor microRNA-101 modulates the cancer epigenome by repressing the polycomb group protein EZH2. Cancer Res. 69, 2623–2629 (2009).
Catto, J. W. et al. Distinct microRNA alterations characterize high- and low-grade bladder cancer. Cancer Res. 69, 8472–8481 (2009).
Hockel, M. & Dornhofer, N. The hydra phenomenon of cancer: why tumors recur locally after microscopically complete resection. Cancer Res. 65, 2997–3002 (2005).
Baffa, R. et al. MicroRNA expression profiling of human metastatic cancers identifies cancer gene targets. J. Pathol. 219, 214–221 (2009).
Veerla, S. et al. MiRNA expression in urothelial carcinomas: important roles of miR-10a, miR-222, miR-125b, miR-7 and miR-452 for tumor stage and metastasis, and frequent homozygous losses of miR-31. Int. J. Cancer 124, 2236–2242 (2009).
Neely, L. A. et al. A microRNA expression ratio defining the invasive phenotype in bladder tumors. Urol. Oncol. 28, 39–48 (2010).
Yang, H. et al. Evaluation of genetic variants in microRNA-related genes and risk of bladder cancer. Cancer Res. 68, 2530–2537 (2008).
Lamy, P. et al. Are microRNAs located in genomic regions associated with cancer? Br. J. Cancer 95, 1415–1418 (2006).
Aaboe, M. et al. SOX4 expression in bladder carcinoma: clinical aspects and in vitro functional characterization. Cancer Res. 66, 3434–3442 (2006).
Ostenfeld, M. S. et al. miR-145 induces caspase-dependent and -independent cell death in urothelial cancer cell lines with targeting of an expression signature present in Ta bladder tumors. Oncogene 29, 1073–1084 (2010).
Lu, Q. et al. MicroRNA-221 silencing predisposed human bladder cancer cells to undergo apoptosis induced by TRAIL. Urol. Oncol. doi:10.1016/j.urolonc.2009.06.005.
Adam, L. et al. miR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy. Clin. Cancer Res. 15, 5060–5072 (2009).
Huang, Y. et al. Microarray analysis of microRNA expression in renal clear cell carcinoma. Eur. J. Surg. Oncol. 35, 1119–1123 (2009).
Nakada, C. et al. Genome-wide microRNA expression profiling in renal cell carcinoma: significant down-regulation of miR-141 and miR-200c. J. Pathol. 216, 418–427 (2008).
Jung, M. et al. MicroRNA profiling of clear cell renal cell cancer identifies a robust signature to define renal malignancy. J. Cell. Mol. Med. 13, 3918–3928 (2009).
Chow, T. F. et al. Differential expression profiling of microRNAs and their potential involvement in renal cell carcinoma pathogenesis. Clin. Biochem. 43, 150–158 (2010).
Kort, E. J. et al. The E2F3–Oncomir-1 axis is activated in Wilms' tumor. Cancer Res. 68, 4034–4038 (2008).
Chow, T. F. et al. The miR-17–92 cluster is over expressed in and has an oncogenic effect on renal cell carcinoma. J. Urol. 183, 743–751 (2010).
Petillo, D. et al. MicroRNA profiling of human kidney cancer subtypes. Int. J. Oncol. 35, 109–114 (2009).
Horikawa, Y. et al. Single nucleotide polymorphisms of microRNA machinery genes modify the risk of renal cell carcinoma. Clin. Cancer Res. 14, 7956–7962 (2008).
Drake, K. M. et al. Loss of heterozygosity at 2q37 in sporadic Wilms' tumor: putative role for miR-562. Clin. Cancer Res. 15, 5985–5992 (2009).
Dutta, K. K. et al. Association of microRNA-34a overexpression with proliferation is cell type-dependent. Cancer Sci. 98, 1845–1852 (2007).
Sinha, S., Dutta, S., Datta, K., Ghosh, A. K. & Mukhopadhyay, D. Von Hippel–Lindau gene product modulates TIS11B expression in renal cell carcinoma: impact on vascular endothelial growth factor expression in hypoxia. J. Biol. Chem. 284, 32610–32618 (2009).
Gillis, A. J. et al. High-throughput microRNAome analysis in human germ cell tumours. J. Pathol. 213, 319–328 (2007).
Looijenga, L. H., Gillis, A. J., Stoop, H., Hersmus, R. & Oosterhuis, J. W. Relevance of microRNAs in normal and malignant development, including human testicular germ cell tumours. Int. J. Androl. 30, 304–314 (2007).
Voorhoeve, P. M. et al. A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors. Cell 124, 1169–1181 (2006).
Novotny, G. W. et al. Analysis of gene expression in normal and neoplastic human testis: new roles of RNA. Int. J. Androl. 30, 316–326 (2007).
Selbach, M. et al. Widespread changes in protein synthesis induced by microRNAs. Nature 455, 58–63 (2008).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Supplementary Table 1
Deregulated miRNAs and their function in prostate cancer (DOC 270 kb)
Supplementary Table 2
Deregulated miRNAs and their function in bladder cancer (DOC 186 kb)
Supplementary Table 3
Deregulated miRNAs and their function in renal cell carcinoma (DOC 130 kb)
Supplementary Table 4
Deregulated miRNAs and their function in Germ Cell Tumors (DOC 39 kb)
Rights and permissions
About this article
Cite this article
Schaefer, A., Stephan, C., Busch, J. et al. Diagnostic, prognostic and therapeutic implications of microRNAs in urologic tumors. Nat Rev Urol 7, 286–297 (2010). https://doi.org/10.1038/nrurol.2010.45
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrurol.2010.45
This article is cited by
-
A machine learning framework develops a DNA replication stress model for predicting clinical outcomes and therapeutic vulnerability in primary prostate cancer
Journal of Translational Medicine (2023)
-
Urine biomarkers in bladder cancer — current status and future perspectives
Nature Reviews Urology (2023)
-
Circulating miR-200a is a novel molecular biomarker for early-stage renal cell carcinoma
ExRNA (2019)
-
Treating metastatic prostate cancer with microRNA-145
Apoptosis (2018)
-
Expression of micro-RNAs and genes related to angiogenesis in ccRCC and associations with tumor characteristics
BMC Urology (2017)